Semler Scientific, Inc. (SMLR) Stock Analysis

Semler Scientific, Inc. (SMLR) Healthcare & Pipeline Overview

Semler Scientific, Inc. delivers technology-driven solutions, notably QuantaFlo, a point-of-care blood flow test, to improve vascular assessment and clinical workflows for healthcare providers in the United States. Targeting cardiologists, nephrologists, and primary care physicians, Semler Scientific operates in the medical device sector, emphasizing efficiency and clinical effectiveness.

What Is the Investment Thesis for SMLR?

Semler Scientific presents a focused investment case centered on its QuantaFlo technology and its potential to expand vascular assessment in primary care settings. With a P/E ratio of 6.2 and a high gross margin of 90.8%, the company demonstrates strong profitability. Growth catalysts include expanding QuantaFlo adoption among primary care physicians and leveraging partnerships with healthcare insurance plans. Key risks involve competition from alternative diagnostic methods and potential changes in reimbursement policies. The company's high profit margin of 130.8% suggests efficient operations, but sustaining this level will be critical. Investors should monitor QuantaFlo's market penetration and Semler's ability to innovate and maintain its competitive edge.

Based on FMP financials and quantitative analysis

SMLR Key Highlights

Market capitalization of $311M reflects its current valuation in the medical device market.

• P/E ratio of 6.2 indicates a potentially undervalued stock relative to its earnings.
• Profit margin of 130.8% demonstrates exceptional profitability and efficient cost management.
• Gross margin of 90.8% highlights the strong pricing power and cost-effectiveness of QuantaFlo.
• Beta of 1.32 suggests higher volatility compared to the overall market.

Who Are SMLR's Competitors?

SMLR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SMLR's Key Strengths?

Proprietary QuantaFlo technology.

• High gross and profit margins.
• Strong customer relationships.
• Efficient point-of-care solution.

What Are SMLR's Weaknesses?

Limited product portfolio.

• Reliance on a single product (QuantaFlo).
• Small company size compared to competitors.
• Potential dependence on key distributors.

What Could Drive SMLR Stock Higher?

SMLR catalyst: Potential new partnerships with major healthcare insurance providers by Q4 2026 could expand QuantaFlo's market access.

• Increasing adoption of QuantaFlo in primary care settings as awareness grows among physicians.
• Positive clinical study results demonstrating the effectiveness of QuantaFlo in early detection of vascular disease.

What Are the Key Risks for SMLR?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Competition from established medical device companies with broader product portfolios.
• Changes in reimbursement policies that could impact the adoption of QuantaFlo.
• Dependence on a single product (QuantaFlo) for the majority of revenue.
• Technological advancements that could render QuantaFlo obsolete.

What Are the Growth Opportunities for SMLR?

• Expanding QuantaFlo adoption in primary care: Semler Scientific can increase its market share by targeting primary care physicians, who are often the first point of contact for patients with vascular symptoms. The market for point-of-care vascular assessment in primary care is estimated to reach $500 million by 2028. By demonstrating the clinical and economic benefits of QuantaFlo, Semler Scientific can drive adoption and increase revenue.
• Leveraging partnerships with healthcare insurance plans: Collaborating with healthcare insurance plans can provide Semler Scientific with access to a large patient population and streamline the reimbursement process. These partnerships can also help to promote the use of QuantaFlo as a cost-effective alternative to traditional diagnostic methods. The market for healthcare insurance partnerships is expected to grow as insurers seek to improve patient outcomes and reduce costs.
• Developing new applications for QuantaFlo technology: Semler Scientific can expand its product portfolio by developing new applications for QuantaFlo technology, such as monitoring blood flow in patients with diabetes or chronic kidney disease. These new applications can open up new markets and revenue streams for the company. The market for vascular assessment in diabetes and kidney disease is estimated to reach $300 million by 2027.
• Expanding into international markets: Semler Scientific can expand its geographic reach by entering international markets, such as Europe and Asia. These markets offer significant growth potential, as they have a large and aging population with a high prevalence of vascular disease. International expansion requires regulatory approvals and adaptation to local healthcare systems, but the potential rewards are substantial.
• Integrating QuantaFlo with telemedicine platforms: Integrating QuantaFlo with telemedicine platforms can enable remote patient monitoring and improve access to vascular assessment for patients in rural or underserved areas. This integration can also help to reduce healthcare costs by eliminating the need for in-office visits. The market for telemedicine is expected to grow rapidly in the coming years, creating new opportunities for Semler Scientific.

What Are SMLR's Competitive Advantages?

• Proprietary QuantaFlo technology provides a unique point-of-care solution.
• Established relationships with key healthcare providers and insurance plans.
• Strong brand reputation for clinical effectiveness and efficiency.
• High gross margins indicate pricing power and cost advantages.

What Does SMLR Do?

Semler Scientific, Inc., established in 2007 and headquartered in Santa Clara, California, focuses on developing, manufacturing, and marketing innovative technology solutions for healthcare providers. The company's flagship product, QuantaFlo, is a non-invasive, point-of-care test that measures blood flow in the extremities, aiding in the diagnosis and management of peripheral arterial disease (PAD) and other vascular conditions. QuantaFlo provides healthcare professionals with objective data to assess a patient's vascular health in just four minutes, directly in the office. The company targets a diverse range of medical specialties, including cardiology, internal medicine, nephrology, endocrinology, podiatry, and family practice. Semler Scientific distributes its products through a combination of direct sales personnel and strategic distribution partnerships, reaching healthcare insurance plans, integrated delivery networks, independent physician groups, and risk assessment companies. Semler Scientific aims to improve clinical outcomes and reduce healthcare costs by providing efficient and effective diagnostic tools for vascular assessment.

What Products and Services Does SMLR Offer?

• Develops and markets QuantaFlo, a point-of-care blood flow testing device.
• Provides technology solutions to improve clinical effectiveness for healthcare providers.
• Offers a non-invasive method for assessing vascular conditions in patients.
• Targets cardiologists, internists, nephrologists, and other specialists.
• Distributes products through salespersons and distributors.
• Aids in the diagnosis and management of peripheral arterial disease (PAD).

How Does SMLR Make Money?

• Generates revenue through the sale of QuantaFlo devices and related services.
• Partners with healthcare providers and insurance plans to promote adoption.
• Focuses on providing cost-effective and efficient diagnostic solutions.
• Employs a direct sales force and distribution network to reach customers.

What Industry Does SMLR Operate In?

Semler Scientific operates within the medical device industry, which is characterized by continuous innovation and stringent regulatory requirements. The market for vascular diagnostic devices is driven by the increasing prevalence of peripheral arterial disease (PAD) and the need for early detection and management. Semler Scientific's QuantaFlo competes with traditional methods like angiography and ultrasound, offering a non-invasive, point-of-care alternative. The industry is also influenced by trends such as telemedicine and remote patient monitoring, which could create new opportunities for Semler Scientific's technology.

Who Are SMLR's Key Customers?

• Cardiologists specializing in vascular health.
• Internists managing patients with chronic conditions.
• Nephrologists treating patients with kidney disease.
• Endocrinologists focusing on diabetes-related vascular complications.
• Healthcare insurance plans seeking cost-effective diagnostic solutions.

Company Profile

Semler Scientific, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Santa Clara, US. The company is led by CEO Douglas Murphy-Chutorian. SMLR has traded publicly since 2014.

How Semler Scientific, Inc. Is Valued

Semler Scientific, Inc. carries a market capitalization of $311M, placing it in the small-cap category.

Return on equity for Semler Scientific, Inc. stands at 5.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.2%, showing how much profit it generates from its asset base. SMLR trades at a trailing price-to-earnings ratio of 6.24, below the Healthcare sector average of ~23x. Its free cash flow yield is -88.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.3%, the inverse of the P/E and a quick read on earnings relative to price.

Semler Scientific, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.12 places it in the grey zone, a middle ground that warrants monitoring.

Wall Street analysts project Semler Scientific, Inc. revenue of about $14.2M for fiscal 2026, with EPS near $-1.92.

SMLR Financials

SMLR Latest News

No recent news available for SMLR.

SMLR Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources